Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Novartis Pharmaceuticals 1-888-669-6682
novartis.email@novartis.com


Novartis Pharmaceuticals +41613241111
novartis.email@novartis.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Back

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

Open to: ALL

Age: 18.0 - N/A

Taunton Bath Leicester London Manchester Sutton London

Medical Conditions

Lymphoma
Carcinoma
Neoplasms
Prostatic Neoplasms
Lymphoma, Large B-Cell, Diffuse
Endometrial Neoplasms
Mesothelioma
Mesothelioma, Malignant
Adenomyoepithelioma
Adenocarcinoma, Clear Cell
Lymphoma, T-Cell
Prostatic Neoplasms, Castration-Resistant

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid tumors and lymphomas.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Sep 2019 Feb 2030

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Tulmimetostat dosed once per day orally in 28 day cycles

Intervention Arm Group : Phase 1;Phase 1 Cohort M8;Phase 2 Cohort M1;Phase 2 Cohort M2;Phase 2 Cohort M3;Phase 2 Cohort M4;Phase 2 Cohort M5;Phase 2 Cohort M6;Phase 2 Cohort M7;Phase 2 Cohort M8;

Intervention Type : DRUG
Intervention Description : Enzalutamide dosed once per day orally in 28 day cycles

Intervention Arm Group : Phase 2 Cohort M8;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Musgrove Park Hospital
    Taunton
    TA1 5DA
  • Royal United Hospital
    Bath
    BA1 3NG
  • University Hospitals of Leicester NHS Trust
    Leicester
    LE5 4PW
  • Royal Marsden Hospital - London
    London
    SW3 6JJ
  • The Christie NHS Foundation Trust, Department of Medical Oncology
    Manchester
    M20 4BX
  • Royal Marsden Hospital - Sutton
    Sutton
    SM2 5PT
  • Imperial College Healthcare NHS Trust
    London
    SW7 2AZ

Novartis Pharmaceuticals +41613241111
novartis.email@novartis.com


Novartis Pharmaceuticals 1-888-669-6682
novartis.email@novartis.com



The study is sponsored by Novartis Pharmaceuticals



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04104776
Last updated 12 May 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top